BlueRock Therapeutics
CompanyUnited States
BlueRock Therapeutics develops one asset, in phase 3 (Bemdaneprocel in Parkinson's disease). Mostly cell therapy acting on stem cell maintenance; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Pluripotent stem cell-derived dopaminergic neuron progenitor cell therapy
Phase 3, Cell therapy, Stem cell maintenance, Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Similar companies6